The trial will focus on the LAmbre Plus Left Atrial Appendage Closure System, a device using left atrial appendage closure to reduce the risk of blood clots, which could cause a stroke in patients with non-valvular atrial fibrillation, according to a Dec. 6 release from the health system. The trial plans to enroll more than 3,000 people.
The trial received approval from the FDA in March and CMS in August, which will allow participating patients to be covered by insurance.
